

# Synthesis of *N*-Benzylhomo-(–)-anisomycin

Guncheol Kim\*, Hyun Woong Hong†, and Sang Hee Lee†

Department of Chemistry, College of Natural Sciences, Chungnam National University, Taejeon 305-764, Korea

†Department of Chemistry, Kunsan National University, Chonbuk 573-701, Korea


Received October 28, 1997

Anisomycin, a fermentation product of various species of *Streptomyces*,<sup>1</sup> is an antibiotic that possesses marked activities against pathogenic protozoa and fungi, and has been used successfully clinically in the treatment of amebic dysentery and trichomonas vaginitis.<sup>2</sup> Considerable synthetic efforts, derivative syntheses as well as total syntheses, have been reported until recently.<sup>3</sup> Especially, the synthesis of its analogues has revealed the structure-activity relationships of synthetic antibiotics.<sup>4</sup> However, few result of the chain extension effect of the *p*-methoxybenzyl group has been reported.

In this respect, this report concerns a new synthetic approach to a *homoanisomycin* analogue **3**. And we considered that intermediate **2** would be suitable for furnishing the desired stereochemistry and the extended side chain of the molecule. The compound **2** can be readily obtained via cis-amidoalkylation of tartramide.<sup>5</sup>

First, in order to set the side group, the allylic amide **2** prepared as described<sup>5</sup> was subjected to ozonolysis and the dimethyl sulfide reductive work-up. Without purification, the corresponding aldehyde was treated with (*p*-methoxyphenyl) magnesium bromide in THF to yield an epimeric mixture of benzylic alcohols in 59% overall yield. The mixture was then reduced by triethylsilane under trifluoroacetic acid treatment in THF. The reducing step under the acidic conditions afforded  $\beta$ -elimination product **6** in less than 10% as well as the desired compound **5** in 70% yield. Compound **6** was readily converted to **5** via catalytic hydrogenation.


The desired acetate functionality at the 3 position could be installed via three step sequence. Firstly, the TBS protection groups were removed to provide a diol by tetrabutylammonium fluoride (TBAF), and the sterically less hindered 4- $\alpha$ -hydroxyl group of the diol was selectively protected with 1.2 equiv. of *tert*-butyldimethylsilyl chloride in DMF at room temperature. Only single isomer was detected. Thirdly, acety-




**Scheme 2.** Reagents and conditions: (a) i.  $O_3$ ,  $CH_2Cl_2$ -MeOH ii. Methyl sulfide (b) (*p*-Methoxyphenyl) magnesium bromide, THF (c)  $Et_3SiH$ ,  $CH_2Cl_2$ , TFA (d) Pd/5%,  $H_2$  (e) TBAF, THF (f) TBSCl, imidazole, DMF (g)  $Ac_2O$ , pyridine (h) TBAF, THF (i)  $BH_3$ -DMS, THF, rt.

lation of the 3-hydroxyl group with acetic anhydride in pyridine provided the acetate **7** in overall yield of 52%. The final steps to the compound **3'** from **7** involved removal of the protecting silyl group with TBAF followed by reduction of the amide group with borane-methyl sulfide complex, affording **3** in 34% overall yield.

In summary, we described a concise synthetic pathway to *N*-benzylhomo-(–)-anisomycin, the first synthetic derivative of homoanisomycins, from the precursor **2**. Further synthetic study of the related analogues is under progress and will be reported in due course.



**Scheme 1.**



**Acknowledgement.** This paper was supported by NON DIRECTED RESEARCH FUND, Korea Research Foundation, 1996.

## References

- Sobin, B. A.; Tanner, F. W., Jr. *J. Am. Chem. Soc.* **1954**, 76, 4053.
- Jiemnez, A.; Vazquez, D. In *Antibiotics*; Hahn, F. E.,

- Ed.; Springer Verlag: Berlin, 1979; vol 5(2). p 1.
3. Kang, S. H.; Choi, H-W. *J. Chem. Soc., Chem. Commun.* **1996**, 1522 and references therein.
4. Hall, S. S.; Loebenberg, D.; Schmarcher, D. P. *J. Med. Chem.* **1983**, 26, 469.
5. Ryu, Y.; Kim, G. *J. Org. Chem.* **1995**, 60, 103.
6. Baer, H.; Zamkane, M. *J. Org. Chem.* **1988**, 53, 4786.
7. **3**:  $[\alpha]_D^{23} - 45.4^\circ$  (c=0.35,  $\text{CHCl}_3$ ),  $^1\text{H}$  NMR (300 MHz

$\text{CDCl}_3$ )  $\delta$  7.4-7.2 (m, 5H) 7.1 (d,  $J=9$  Hz, 2H), 6.8 (d,  $J=9$  Hz, 2H), 4.8 (dd,  $J=2.4, 2.4$  Hz, 1H), 4.1 (td,  $J=6.3, 2.4$  Hz, 1H), 4.0 (d,  $J=13$  Hz, 1H), 3.8 (s, 3H), 3.3 (d,  $J=13$  Hz, 1H), 3.2 (dd,  $J=8, 6.6$  Hz, 1H) 2.9 (br. s, 1H), 2.7 (m, 1H), 2.4-2.7 (m, 2H), 2.2 (s, 3H), 2.1 (m, 1H), 1.9-2.1 (m, 2H), IR ( $\text{CHCl}_3$ ) 3430, 3054, 2987, 2361, 1699, 1540, 1421, 1265, 896, 738  $\text{cm}^{-1}$ , MS (FAB, glycerol) 370 ( $\text{M}^+$ )